Nurix Therapeutics
NRIX
130 hedge funds and large institutions have $508M invested in Nurix Therapeutics in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 23 closing their positions.
843% more call options, than puts
Call options by funds: $575K | Put options by funds: $61K
44% more capital invested
Capital invested by funds: $352M → $508M (+$155M)
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
8.48% more ownership
Funds ownership: 92.99% → 101.47% (+8.5%)
2% more funds holding
Funds holding: 128 → 130 (+2)
9% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$41.2M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$4.92M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.13M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.32M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$9.63M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.84M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$5.58M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.6M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$4.38M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Simplex Trading
Chicago,
Illinois
| – | -$7.13K | -1,041 | -94% |
|
|
PMEF
152
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$5.12K | -651 | Closed |
|
|
LC
153
Lindbrook Capital
Calabasas,
California
| – | -$2.62K | -333 | Closed |
|
NRIX Hedge Fund Activity: Q4 2023 in Review
130 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2023, worth a combined $508M — up 44% from $352M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NRIX positions and 23 closed out — a net gain of 2 holders — while 45 added to existing stakes and 38 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $41.2M. The largest seller was Boxer Capital, exiting entirely with an estimated $9.63M sold.
- 130 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2023, up from 128 in Q3 2023.
- Funds reported $508M of Nurix Therapeutics stock for Q4 2023, up 44% quarter-over-quarter.
- 25 funds opened new Nurix Therapeutics positions in Q4 2023 and 23 closed out, a net change of +2 holders.
- The largest Nurix Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $41.2M added.
- The largest Nurix Therapeutics seller in Q4 2023 was Boxer Capital, an estimated $9.63M sold.
Based on aggregated 13F filings for Q4 2023.